The Brighterside of News on MSN
Scientists create special antibody that shuts down rogue T cells safely
A promising breakthrough in autoimmune disease research may open the door to safer and more effective treatments. Scientists ...
GAITHERSBURG, Md., US, November 7, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...
Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...
Researchers have identified special immune cells in the brain that help slow Alzheimer’s. These microglia work to reduce ...
12d
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with ...
CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory ...
The first patient has been dosed in a Phase 1 trial testing the experimental CAR T-cell therapy obecabtagene autoleucel for progressive MS.
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
Community-based CAR T-cell therapy improves access, reducing travel burdens and hospital admissions for patients with blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback